Along with their ability to hamper HGF/MET signaling in a number of biochemical and biological assays, these antibodies displayed anti-tumor and/or anti-metastatic activity in preclinical models of HGF-dependent glioblastoma, triple-negative breast cancer, and colorectal cancer. This evidence concerns the gene HGF and colorectal cancer.